Semaglutide as a GLP-1 Receptor Agonist: the Evidence Behind How It Works

Why the GLP-1 pathway matters for weight loss, and what semaglutide does to it

GLP-1 is released from the gut within minutes of eating. It signals to the hypothalamus that food has arrived, damps down appetite, and slows gastric emptying so you feel full for longer. In people living with obesity, GLP-1 signalling after a meal can be blunted, the satiety message arrives quietly, if at all. Semaglutide is engineered to bind to GLP-1 receptors with far greater persistence than the natural hormone, which breaks down in the bloodstream within minutes. A small structural modification allows semaglutide to attach to albumin in the blood, extending its half-life to around seven days and making once-weekly dosing practical.

That mechanism explains the clinical picture. Patients consistently report eating less, feeling satisfied on smaller portions, and losing interest in foods they previously craved. The NHS medicines information on semaglutide describes it as reducing appetite and food intake through these central and peripheral GLP-1 effects. Because it acts on multiple sites (brainstem, hypothalamus, gut smooth muscle) the appetite reduction is sustained rather than a brief suppression. That is meaningfully different from older appetite medicines that worked on adrenaline pathways.

The single GLP-1 receptor activation is also why semaglutide is often compared with tirzepatide, which activates both GLP-1 and GIP receptors. Tirzepatide's dual mechanism appears to produce greater average weight loss in head-to-head data. Whether that difference matters for a given person is a clinical question, not a marketing one. You can read more about how semaglutide fits into the broader GLP-1 medicine landscape if you want to understand the receptor-level distinctions before a consultation.

What STEP 1 showed, and how to read the numbers honestly

The STEP 1 trial remains the pivotal evidence base. It randomised 1,961 adults with obesity or overweight plus a weight-related condition, with no type 2 diabetes, to either semaglutide 2.4mg weekly or placebo for 68 weeks. The semaglutide group lost an average of approximately 15% of body weight; the placebo group lost around 2.4%. Around a third of semaglutide participants lost 20% or more. These are averages across a population, not a prediction for any individual, some people lost considerably more, some less, and some found the side effects limited how far they could titrate.

The MHRA approved Wegovy for weight management on the basis of this evidence and related STEP programme data. In April 2026 it approved a dedicated 7.2mg single-dose pen, after trials at that higher dose showed average weight loss of around 20.7% over 72 weeks, closing some of the gap with tirzepatide at its highest dose. The 7.2mg pen is licensed for BMI of 30 or above only, and titration still starts at 0.25mg. How semaglutide's GLP-1 action compares across doses is a question worth raising at your clinical review, since the prescriber will determine which pathway suits you.

Cost is a practical consideration too. Reviewing the treatment options available through nume gives a clear picture of what private semaglutide treatment includes (consultation, prescription, clinical review and delivery) and the context behind why pricing varies between providers.

Eligibility, the licence boundary, and the Ozempic confusion

Wegovy is licensed in the UK for adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition such as high blood pressure, high cholesterol, or obstructive sleep apnoea. NICE recommends semaglutide for weight management within specialist services for a maximum of two years, targeting those with a BMI of 35 or above and at least one comorbidity. Ethnic-background adjustments of 2.5 kg/m² lower apply for several groups under NICE's technology appraisal TA875. Private prescribing follows the licensed SmPC criteria, and a prescriber assesses the full clinical picture rather than BMI alone.

Two other semaglutide products cause regular confusion. Ozempic is the same molecule at lower weekly doses (0.5mg and 1mg), licensed solely for type 2 diabetes, it is not legally prescribed for weight loss and should not be sought for that purpose. Rybelsus is oral semaglutide at 3mg, 7mg and 14mg, again licensed for type 2 diabetes only. The weight-management oral version (Wegovy tablets, approved by the MHRA in June 2026) uses a completely different dose ladder (1.5mg, 4mg, 9mg, 25mg). These products are related by molecule but separated by licence. Presenting Ozempic as a weight-loss medicine to a prescriber is asking them to prescribe off-label in a context the regulator has not approved.

If you are thinking about whether semaglutide is the right option for you, the starting point is a clinical consultation, not a price comparison. Semaglutide is not suitable during pregnancy, breastfeeding, or if you are actively trying to conceive; it is also not licensed for under-18s. History of certain conditions including pancreatitis or medullary thyroid cancer requires careful prescriber discussion before any GLP-1 medicine, a category that includes semaglutide and works through a shared receptor pathway.

Taking it practically: routine, storage, and what to watch for

Wegovy injections are once weekly, most people pick a consistent day and keep their pen in the fridge door beside everyday items so it becomes part of the weekly routine rather than a clinical event. Storage is at 2–8°C; the SmPC specifies a limited window for room-temperature use that you should check in your patient information leaflet rather than rely on a general figure online.

Side effects follow the pattern you would predict from the mechanism. Slowing gastric emptying means nausea, constipation, and reflux are the most common complaints, particularly in the early weeks of a new dose. These typically settle as the body adjusts. More serious but infrequent effects (acute pancreatitis among them) prompted the MHRA to issue a Drug Safety Update for GLP-1 medicines in January 2026. Severe stomach pain that spreads to the back, especially alongside vomiting, warrants urgent medical assessment rather than waiting for it to pass. Suspected side effects can be reported at the MHRA's Yellow Card scheme.

If you are researching where to access Wegovy, this page covers the UK sourcing routes and what to check about any online provider. All legitimate routes require a prescription following clinical assessment, semaglutide supplied without that step falls outside the law and carries real safety risks from unverified product. Our clinical team reviews every consultation personally before anything is prescribed or dispatched.